 | • レポートコード：MRC2Q12-19282 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、新型コロナウイルス不活化ワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 新型コロナウイルス不活化ワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 新型コロナウイルス不活化ワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 新型コロナウイルス不活化ワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの新型コロナウイルス不活化ワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の新型コロナウイルス不活化ワクチンの売上および2028年までの予測に焦点を当てています。 新型コロナウイルス不活化ワクチンのグローバル主要企業には、Inovio Pharmaceuticals、Moderna、GlaxoSmithKine、Pfizer、Johnson&Johnson、Heat Biologics、Sanofi、Beijing Institute of Biological Products Co., Ltd、Beijing Kexing Zhongwei Biotechnology Co., Ltd、Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd、Wuhan Institute of Biological Products Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 新型コロナウイルス不活化ワクチン市場は、タイプとアプリケーションによって区分されます。世界の新型コロナウイルス不活化ワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 大人間、小人 【アプリケーション別セグメント】 病院、クリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 新型コロナウイルス不活化ワクチン製品概要 - タイプ別市場（大人間、小人） - アプリケーション別市場（病院、クリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の新型コロナウイルス不活化ワクチン販売量予測2017-2028 - 世界の新型コロナウイルス不活化ワクチン売上予測2017-2028 - 新型コロナウイルス不活化ワクチンの地域別販売量 - 新型コロナウイルス不活化ワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別新型コロナウイルス不活化ワクチン販売量 - 主要メーカー別新型コロナウイルス不活化ワクチン売上 - 主要メーカー別新型コロナウイルス不活化ワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（大人間、小人） - 新型コロナウイルス不活化ワクチンのタイプ別販売量 - 新型コロナウイルス不活化ワクチンのタイプ別売上 - 新型コロナウイルス不活化ワクチンのタイプ別価格 ・アプリケーション別市場規模（病院、クリニック） - 新型コロナウイルス不活化ワクチンのアプリケーション別販売量 - 新型コロナウイルス不活化ワクチンのアプリケーション別売上 - 新型コロナウイルス不活化ワクチンのアプリケーション別価格 ・北米市場 - 北米の新型コロナウイルス不活化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の新型コロナウイルス不活化ワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの新型コロナウイルス不活化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の新型コロナウイルス不活化ワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の新型コロナウイルス不活化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の新型コロナウイルス不活化ワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の新型コロナウイルス不活化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の新型コロナウイルス不活化ワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの新型コロナウイルス不活化ワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の新型コロナウイルス不活化ワクチン市場規模（トルコ、サウジアラビア） ・企業情報 Inovio Pharmaceuticals、Moderna、GlaxoSmithKine、Pfizer、Johnson&Johnson、Heat Biologics、Sanofi、Beijing Institute of Biological Products Co., Ltd、Beijing Kexing Zhongwei Biotechnology Co., Ltd、Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd、Wuhan Institute of Biological Products Co., Ltd ・産業チェーン及び販売チャネル分析 - 新型コロナウイルス不活化ワクチンの産業チェーン分析 - 新型コロナウイルス不活化ワクチンの原材料 - 新型コロナウイルス不活化ワクチンの生産プロセス - 新型コロナウイルス不活化ワクチンの販売及びマーケティング - 新型コロナウイルス不活化ワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 新型コロナウイルス不活化ワクチンの産業動向 - 新型コロナウイルス不活化ワクチンのマーケットドライバー - 新型コロナウイルス不活化ワクチンの課題 - 新型コロナウイルス不活化ワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Novel Coronavirus Inactivated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Novel Coronavirus Inactivated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Novel Coronavirus Inactivated Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Novel Coronavirus Inactivated Vaccine include Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson&Johnson, Heat Biologics, Sanofi, Beijing Institute of Biological Products Co., Ltd and Beijing Kexing Zhongwei Biotechnology Co., Ltd, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Novel Coronavirus Inactivated Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Novel Coronavirus Inactivated Vaccine market. Further, it explains the major drivers and regional dynamics of the global Novel Coronavirus Inactivated Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Inovio Pharmaceuticals
Moderna
GlaxoSmithKine
Pfizer
Johnson&Johnson
Heat Biologics
Sanofi
Beijing Institute of Biological Products Co., Ltd
Beijing Kexing Zhongwei Biotechnology Co., Ltd
Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
Wuhan Institute of Biological Products Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Novel Coronavirus Inactivated Vaccine Segment by Type
Adult
Child
Novel Coronavirus Inactivated Vaccine Segment by Application
Hospital
Clinic
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Novel Coronavirus Inactivated Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Novel Coronavirus Inactivated Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Novel Coronavirus Inactivated Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Novel Coronavirus Inactivated Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Novel Coronavirus Inactivated Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Novel Coronavirus Inactivated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Novel Coronavirus Inactivated Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Inovio Pharmaceuticals, Moderna, GlaxoSmithKine, Pfizer, Johnson&Johnson, Heat Biologics, Sanofi, Beijing Institute of Biological Products Co., Ltd and Beijing Kexing Zhongwei Biotechnology Co., Ltd, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Novel Coronavirus Inactivated Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Novel Coronavirus Inactivated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Novel Coronavirus Inactivated Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Novel Coronavirus Inactivated Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Novel Coronavirus Inactivated Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Adult
1.2.3 Child
1.3 Market by Application
1.3.1 Global Novel Coronavirus Inactivated Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Novel Coronavirus Inactivated Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Novel Coronavirus Inactivated Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Novel Coronavirus Inactivated Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Novel Coronavirus Inactivated Vaccine Sales by Region
2.4.1 Global Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Novel Coronavirus Inactivated Vaccine by Region (2023-2028)
2.5 Global Novel Coronavirus Inactivated Vaccine Revenue by Region
2.5.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2022)
2.5.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Novel Coronavirus Inactivated Vaccine Sales by Manufacturers
3.1.1 Global Top Novel Coronavirus Inactivated Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Novel Coronavirus Inactivated Vaccine in 2021
3.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Manufacturers
3.2.1 Global Novel Coronavirus Inactivated Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Novel Coronavirus Inactivated Vaccine Revenue in 2021
3.3 Global Novel Coronavirus Inactivated Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Novel Coronavirus Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Novel Coronavirus Inactivated Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Novel Coronavirus Inactivated Vaccine Sales by Type
4.1.1 Global Novel Coronavirus Inactivated Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Novel Coronavirus Inactivated Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Type
4.2.1 Global Novel Coronavirus Inactivated Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Novel Coronavirus Inactivated Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Novel Coronavirus Inactivated Vaccine Price by Type
4.3.1 Global Novel Coronavirus Inactivated Vaccine Price by Type (2017-2022)
4.3.2 Global Novel Coronavirus Inactivated Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Novel Coronavirus Inactivated Vaccine Sales by Application
5.1.1 Global Novel Coronavirus Inactivated Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Novel Coronavirus Inactivated Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Novel Coronavirus Inactivated Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Novel Coronavirus Inactivated Vaccine Revenue by Application
5.2.1 Global Novel Coronavirus Inactivated Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Novel Coronavirus Inactivated Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Novel Coronavirus Inactivated Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Novel Coronavirus Inactivated Vaccine Price by Application
5.3.1 Global Novel Coronavirus Inactivated Vaccine Price by Application (2017-2022)
5.3.2 Global Novel Coronavirus Inactivated Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Novel Coronavirus Inactivated Vaccine Market Size by Type
6.1.1 North America Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2028)
6.1.2 North America Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2028)
6.2 North America Novel Coronavirus Inactivated Vaccine Market Size by Application
6.2.1 North America Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2028)
6.2.2 North America Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2028)
6.3 North America Novel Coronavirus Inactivated Vaccine Market Size by Country
6.3.1 North America Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2028)
6.3.2 North America Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Novel Coronavirus Inactivated Vaccine Market Size by Type
7.1.1 Europe Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2028)
7.1.2 Europe Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2028)
7.2 Europe Novel Coronavirus Inactivated Vaccine Market Size by Application
7.2.1 Europe Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2028)
7.2.2 Europe Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2028)
7.3 Europe Novel Coronavirus Inactivated Vaccine Market Size by Country
7.3.1 Europe Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2028)
7.3.2 Europe Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Novel Coronavirus Inactivated Vaccine Market Size by Type
8.1.1 Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Novel Coronavirus Inactivated Vaccine Market Size by Application
8.2.1 Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Novel Coronavirus Inactivated Vaccine Market Size by Region
8.3.1 Asia Pacific Novel Coronavirus Inactivated Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Novel Coronavirus Inactivated Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Novel Coronavirus Inactivated Vaccine Market Size by Type
9.1.1 Latin America Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2028)
9.2 Latin America Novel Coronavirus Inactivated Vaccine Market Size by Application
9.2.1 Latin America Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2028)
9.3 Latin America Novel Coronavirus Inactivated Vaccine Market Size by Country
9.3.1 Latin America Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Novel Coronavirus Inactivated Vaccine Market Size by Type
10.1.1 Middle East and Africa Novel Coronavirus Inactivated Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Novel Coronavirus Inactivated Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Novel Coronavirus Inactivated Vaccine Market Size by Application
10.2.1 Middle East and Africa Novel Coronavirus Inactivated Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Novel Coronavirus Inactivated Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Novel Coronavirus Inactivated Vaccine Market Size by Country
10.3.1 Middle East and Africa Novel Coronavirus Inactivated Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Novel Coronavirus Inactivated Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Inovio Pharmaceuticals
11.1.1 Inovio Pharmaceuticals Corporation Information
11.1.2 Inovio Pharmaceuticals Overview
11.1.3 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Inovio Pharmaceuticals Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Inovio Pharmaceuticals Recent Developments
11.2 Moderna
11.2.1 Moderna Corporation Information
11.2.2 Moderna Overview
11.2.3 Moderna Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Moderna Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Moderna Recent Developments
11.3 GlaxoSmithKine
11.3.1 GlaxoSmithKine Corporation Information
11.3.2 GlaxoSmithKine Overview
11.3.3 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GlaxoSmithKine Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GlaxoSmithKine Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Pfizer Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Johnson&Johnson
11.5.1 Johnson&Johnson Corporation Information
11.5.2 Johnson&Johnson Overview
11.5.3 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Johnson&Johnson Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Johnson&Johnson Recent Developments
11.6 Heat Biologics
11.6.1 Heat Biologics Corporation Information
11.6.2 Heat Biologics Overview
11.6.3 Heat Biologics Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Heat Biologics Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Heat Biologics Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sanofi Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
11.8 Beijing Institute of Biological Products Co., Ltd
11.8.1 Beijing Institute of Biological Products Co., Ltd Corporation Information
11.8.2 Beijing Institute of Biological Products Co., Ltd Overview
11.8.3 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Beijing Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
11.9 Beijing Kexing Zhongwei Biotechnology Co., Ltd
11.9.1 Beijing Kexing Zhongwei Biotechnology Co., Ltd Corporation Information
11.9.2 Beijing Kexing Zhongwei Biotechnology Co., Ltd Overview
11.9.3 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Beijing Kexing Zhongwei Biotechnology Co., Ltd Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Beijing Kexing Zhongwei Biotechnology Co., Ltd Recent Developments
11.10 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd
11.10.1 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Corporation Information
11.10.2 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Overview
11.10.3 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Shanghai Pharmaceutical CanSino Biopharmaceutical Co., Ltd Recent Developments
11.11 Wuhan Institute of Biological Products Co., Ltd
11.11.1 Wuhan Institute of Biological Products Co., Ltd Corporation Information
11.11.2 Wuhan Institute of Biological Products Co., Ltd Overview
11.11.3 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Wuhan Institute of Biological Products Co., Ltd Novel Coronavirus Inactivated Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Novel Coronavirus Inactivated Vaccine Industry Chain Analysis
12.2 Novel Coronavirus Inactivated Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Novel Coronavirus Inactivated Vaccine Production Mode & Process
12.4 Novel Coronavirus Inactivated Vaccine Sales and Marketing
12.4.1 Novel Coronavirus Inactivated Vaccine Sales Channels
12.4.2 Novel Coronavirus Inactivated Vaccine Distributors
12.5 Novel Coronavirus Inactivated Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Novel Coronavirus Inactivated Vaccine Industry Trends
13.2 Novel Coronavirus Inactivated Vaccine Market Drivers
13.3 Novel Coronavirus Inactivated Vaccine Market Challenges
13.4 Novel Coronavirus Inactivated Vaccine Market Restraints
14 Key Findings in The Global Novel Coronavirus Inactivated Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer